Shannon Mumenthaler, PhD, is an Assistant Professor of Medicine and Biomedical Engineering at the University of Southern California. She is also the Laboratory Director for the Ellison Institute, which is a translational institute that bridges research and innovation by bringing together researchers, patients, and physicians dedicated to improving human health. Although Dr. Mumenthaler’s primary scientific training is in cell biology, she applies a unique multidisciplinary approach toward her research program, partnering with mathematicians, clinicians and engineers to explore critical areas in cancer. Her overall research interest focuses on the importance of the tumor microenvironment in influencing tumor progression and treatment response. She is developing physiologically-relevant model systems that capture the microenvironmental context of a tumor and coupling these preclinical models with microscopy-based imaging pipelines to provide deeper insights into the evolving tumor.

Neil Carragher is Professor of Drug Discovery at the University of Edinburgh, he graduated from the University of Aberdeen, Scotland UK in 1992 with a B.Sc Honours degree in the subject of “Cell and Immunobiology”.  He then took up a position within industry at the Yamanouchi Research Institute, Oxford, England UK where he also gained his PhD. He then held consecutive postdoctoral positions within the Department of Pathology, University of Washington, Seattle, USA and at the Beatson Institute for Cancer Research, Glasgow, Scotland UK. In 2004 Neil returned to the pharmaceutical industry as Principal Scientist with the Advanced Science and Technology Laboratory at AstraZeneca where he pioneered early multiparametric high-content phenotypic screening approaches. In 2010 he once again made the career switch from industry to academia and took up the post of Principal Investigator of Drug Discovery at the University of Edinburgh where he leads a research group and is currently co-director of the Edinburgh Cancer Discovery Unit and the Edinburgh Phenotypic Assay Centre. Primary research interests include advancing High-content analysis, phenotypic screening, Reverse Phase Protein Array technology, drug combinations and cancer drug discovery. Neil is also Chief Scientific Officer of the Phenomics Discovery initiative, a public-private consortia to advance phenotypic screening technologies https://npsc.ac.uk/pdi and is a founding member of the European Cell Based Assay Interest group www.eucai.org and global RPPA society.

Bartek Rajwa has more than 25 years of experience in single-cell analysis, including imaging and flow cytometry. He is a Associate Research Professor of Computational Life Sciences in the Bindley Bioscience Center at Purdue University, where he is conducting studies on the technologies of biological pattern recognition, high-throughput cytometry, high-content imaging, biological-image analysis, and applications of statistical machine learning in cell biology, cancer research, and neuroscience. Dr. Rajwa’s studies employ mathematical models to decipher and interpret complex phenotypic patterns observed via quantitative cell analysis. Working with collaborators, Dr. Rajwa developed new technologies for biological data science, including automated pipelines for clinical flow cytometry analysis, microorganism identification algorithms, and spectral information processing approaches for fluorescence and Raman cytometry. He has also been a co-inventor of two breakthrough hardware technologies: multispectral flow cytometry (licensed by Sony Biotechnology and by Propel Labs.) and elastic light scatter microorganism identification system. Dr. Rajwa is also an Associate Editor of Cytometry Part A (the official journal of the International Society for Advancement of Cytometry), where he is responsible for this journal’s computational cytometry and imaging content.

Todd Shelper is a research fellow at the Menzies Health Institute Queensland, working on cell-based therapies for The Spinal Injury Project. He obtained his PhD from Griffith University in 2014 with his project focusing on the development of more physiologically relevant in vitro 3D pancreatic cancer models for use in anti-cancer drug discovery programs. During his time at Griffith University, he has worked on commercial anti-infective high throughput screening and lead optimisation projects. He is actively involved in developing primarily imaging-based assays and has run numerous HTS and HCS campaigns across a range of biology including oncology and parasitology. Todd is currently investigating the therapeutic potential of transplanting olfactory glia in pre-clinical spinal injury models. He has been a board member with the society for 3 years and participated in educational seminars and event planning at the annual SBI² meetings.

Judi Wardwell-Swanson is a Sr. Application Scientist at InSphero, Inc. where she assists Pharma, Biotech and Academic scientists integrate multicellular 3D models derived from human donor tissues into their drug discovery workflow. In addition to her role as InSphero’s Senior Application Scientist, she also serves as the lead scientist for their high content imaging strategy and technical advisor for their newly acquired imaging platform. Judi has been an active member of SBI2 for 5 years, serving as a Councilor on the Board of Directors from 2016-2019 .

Dave has been a practitioner of flow cytometry for forty years and image cytometry for seventeen years. He most recently was in the Primary Pharmacology Group in Pfizer, Groton, CT supporting early drug discovery programs with both flow and image cytometry. He is currently semi-retired and is involved with Cytek Biosciences supporting the Aurora Cytometry platform featuring full spectrum flow cytometry.